Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 21 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its oncology injectable manufacturing facility in Ahmedabad. The report indicates that the facility's classification has improved from Official Action Indicated to Voluntary Action Indicated following a recent inspection. This disclosure is made in accordance with regulatory requirements to inform investors and exchange members.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Re.: Press Release Please find enclosed a copy of press release dated September 21, 2025, titled “Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad” The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. DHAVAL NARENDRA SONI DHAVAL N. SONI COMPANY SECRETARY

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases